{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:59:03Z","timestamp":1788274743216,"version":"build-2803163510"},"reference-count":145,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1081122"],"award-info":[{"award-number":["OPP1081122"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0007860","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T18:26:25Z","timestamp":1580408785000},"page":"e0007860","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Reassessing therapeutic antibodies for neglected and tropical diseases"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2261-9424","authenticated-orcid":false,"given":"Rob","family":"Hooft van Huijsduijnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somei","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-0059","authenticated-orcid":true,"given":"Dee","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisafumi","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Akahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N. C.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"pntd.0007860.ref001","unstructured":"ACTIP. Monoclonal Antibodies Approved by the EMA and FDA for Therapeutic Use (status 2017). http:\/\/www.actip.org\/products\/monoclonal-antibodies-approved-by-the-ema-and-fda-for-therapeutic-use\/. 2017. [cited 2020 Jan 11]."},{"issue":"2","key":"pntd.0007860.ref002","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/d41573-019-00014-x","article-title":"2018 FDA drug approvals","volume":"18","author":"A. Mullard","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"pntd.0007860.ref003","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/d41573-019-00004-z","article-title":"2018 FDA approvals hit all time high\u2014but average value slips again","volume":"18","author":"M Baedeker","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"pntd.0007860.ref004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","article-title":"Antibodies to watch in 2019","volume":"11","author":"H Kaplon","year":"2019","journal-title":"mAbs"},{"key":"pntd.0007860.ref005","unstructured":"Kalorama Information. What's Trending in Monoclonal Antibodies (Markets by Structure, by Target, and by Indication)https:\/\/kaloramainformation.com\/product\/whats-trending-in-monoclonal-antibodies-market-by-structure-chimeric-humanized-by-target-egfr-tnf-her2-cd20pd-1-other-and-by-disease-autoimmune-oncology-neurological-other\/. 2017. [cited 2020 Jan 11]."},{"issue":"12","key":"pntd.0007860.ref006","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s00216-019-01714-4","article-title":"The 2018 Nobel Prize in Chemistry: phage display of peptides and antibodies","volume":"411","author":"R Barderas","year":"2019","journal-title":"Analytical and bioanalytical chemistry"},{"issue":"8","key":"pntd.0007860.ref007","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm1080","article-title":"An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus","volume":"10","author":"E Traggiai","year":"2004","journal-title":"Nat Med"},{"key":"pntd.0007860.ref008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jim.2014.11.003","article-title":"Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies","volume":"416","author":"EL Silveira","year":"2015","journal-title":"J Immunol Methods"},{"issue":"1","key":"pntd.0007860.ref009","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"J Wrammert","year":"2011","journal-title":"J Exp Med"},{"issue":"1","key":"pntd.0007860.ref010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"M Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"pntd.0007860.ref011","article-title":"Immune checkpoint blockade in infectious diseases","author":"MN Wykes","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"pntd.0007860.ref012","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"V Verma","year":"2018","journal-title":"Journal for immunotherapy of cancer"},{"issue":"7","key":"pntd.0007860.ref013","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40265-018-0907-5","article-title":"Ibalizumab: First Global Approval","volume":"78","author":"A. Markham","year":"2018","journal-title":"Drugs"},{"issue":"10098","key":"pntd.0007860.ref014","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"T Shi","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"pntd.0007860.ref015","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants","volume":"37","author":"JB Domachowske","year":"2018","journal-title":"The Pediatric infectious disease journal"},{"issue":"5","key":"pntd.0007860.ref016","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","article-title":"Industrialization of mAb production technology: the bioprocessing industry at a crossroads","volume":"1","author":"B. Kelley","year":"2009","journal-title":"mAbs"},{"key":"pntd.0007860.ref017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ces.2015.10.029","article-title":"Cost evaluation of antibody production processes in different operation modes","volume":"141","author":"S Klutz","year":"2016","journal-title":"Chemical Engineering Science"},{"issue":"4","key":"pntd.0007860.ref018","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/btpr.2492","article-title":"Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture","volume":"33","author":"J Pollock","year":"2017","journal-title":"Biotechnology progress"},{"issue":"1","key":"pntd.0007860.ref019","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12936-018-2549-1","article-title":"Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria","volume":"17","author":"F Macintyre","year":"2018","journal-title":"Malar J"},{"key":"pntd.0007860.ref020","unstructured":"UNITAID. Seasonal malaria chemoprevention for children in the Sahel. https:\/\/unitaidorg\/project\/seasonal-malaria-chemo-prevention-children-sahel\/#en. 2017. [cited 2020 Jan 11]."},{"issue":"1","key":"pntd.0007860.ref021","first-page":"20","article-title":"Mechanistic considerations for the use of monoclonal antibodies for cancer therapy","volume":"11","author":"PM Glassman","year":"2014","journal-title":"Cancer biology & medicine"},{"issue":"2","key":"pntd.0007860.ref022","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","article-title":"Strategies to extend plasma half-lives of recombinant antibodies","volume":"23","author":"RE Kontermann","year":"2009","journal-title":"BioDrugs"},{"issue":"4","key":"pntd.0007860.ref023","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development\u2014Progress, remaining challenges and future innovations","volume":"3","author":"JK Liu","year":"2014","journal-title":"Annals of medicine and surgery"},{"issue":"6","key":"pntd.0007860.ref024","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"RE Kontermann","year":"2011","journal-title":"Curr Opin Biotechnol"},{"issue":"2","key":"pntd.0007860.ref025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"J Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"4","key":"pntd.0007860.ref026","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"FH Priddy","year":"2019","journal-title":"Lancet HIV"},{"issue":"5","key":"pntd.0007860.ref027","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.nbt.2011.03.018","article-title":"Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology","volume":"28","author":"JD Berry","year":"2011","journal-title":"New biotechnology"},{"issue":"12","key":"pntd.0007860.ref028","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.vaccine.2013.01.025","article-title":"Monoclonal antibodies for prophylactic and therapeutic use against viral infections","volume":"31","author":"L Both","year":"2013","journal-title":"Vaccine"},{"key":"pntd.0007860.ref029","first-page":"413","article-title":"Immune evasion, a critical strategy for rabies virus","volume":"131","author":"M. Lafon","year":"2008","journal-title":"Developments in biologicals"},{"issue":"1","key":"pntd.0007860.ref030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13238-017-0433-3","article-title":"Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy","volume":"9","author":"Y Mimura","year":"2018","journal-title":"Protein & cell"},{"key":"pntd.0007860.ref031","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2471\/BLT.16.178061","article-title":"Therapeutic antibodies for infectious diseases","volume":"95","author":"E Sparrow","year":"2017","journal-title":"Bull World Health Organ"},{"issue":"2","key":"pntd.0007860.ref032","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.abb.2012.06.001","article-title":"Anti-bacterial monoclonal antibodies: back to the future?","volume":"526","author":"MB Oleksiewicz","year":"2012","journal-title":"Arch Biochem Biophys"},{"key":"pntd.0007860.ref033","first-page":"1320","article-title":"Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration \"Animal Rule\"","volume":"6","author":"CW Tsai","year":"2015","journal-title":"Frontiers in microbiology"},{"key":"pntd.0007860.ref034","first-page":"1","article-title":"How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases?","author":"AH Laustsen","year":"2019","journal-title":"Expert opinion on drug discovery"},{"key":"pntd.0007860.ref035","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1038\/nrdp.2017.79","article-title":"Snakebite envenoming","volume":"3","author":"JM Gutierrez","year":"2017","journal-title":"Nature reviews Disease primers"},{"issue":"34","key":"pntd.0007860.ref036","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.2174\/1381612822666160623073438","article-title":"From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy","volume":"22","author":"AH Laustsen","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"7623","key":"pntd.0007860.ref037","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/538041e","article-title":"Snakebites: costing recombinant antivenoms","volume":"538","author":"AH Laustsen","year":"2016","journal-title":"Nature"},{"issue":"2","key":"pntd.0007860.ref038","doi-asserted-by":"crossref","first-page":"e0005361","DOI":"10.1371\/journal.pntd.0005361","article-title":"Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?","volume":"11","author":"AH Laustsen","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0007860.ref039","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10080309","article-title":"Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms","volume":"10","author":"AH Laustsen","year":"2018","journal-title":"Toxins"},{"issue":"12","key":"pntd.0007860.ref040","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nrd4197","article-title":"The GHIT fund shows its cards","volume":"12","author":"D. Holmes","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"pntd.0007860.ref041","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/S2214-109X(13)70055-X","article-title":"The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations","volume":"1","author":"BT Slingsby","year":"2013","journal-title":"The Lancet Global health"},{"issue":"1","key":"pntd.0007860.ref042","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","article-title":"Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine","volume":"19","author":"A Wilder-Smith","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"pntd.0007860.ref043","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41541-016-0003-3","article-title":"A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus","volume":"2","author":"M Xu","year":"2017","journal-title":"NPJ Vaccines"},{"key":"pntd.0007860.ref044","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.antiviral.2017.05.007","article-title":"Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates","volume":"144","author":"EZ Ong","year":"2017","journal-title":"Antiviral research"},{"issue":"2","key":"pntd.0007860.ref045","doi-asserted-by":"crossref","first-page":"e0006209","DOI":"10.1371\/journal.pntd.0006209","article-title":"Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein","volume":"12","author":"Y Budigi","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0007860.ref046","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bbrc.2012.06.057","article-title":"Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection","volume":"423","author":"C Setthapramote","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"pntd.0007860.ref047","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.antiviral.2013.03.018","article-title":"Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection","volume":"98","author":"T Sasaki","year":"2013","journal-title":"Antiviral research"},{"key":"pntd.0007860.ref048","doi-asserted-by":"crossref","first-page":"e4021","DOI":"10.7717\/peerj.4021","article-title":"Generation and characterization of cross neutralizing human monoclonal antibody against 4 serotypes of dengue virus without enhancing activity","volume":"5","author":"S Injampa","year":"2017","journal-title":"PeerJ"},{"issue":"5","key":"pntd.0007860.ref049","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.4269\/ajtmh.16-0319","article-title":"Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates","volume":"95","author":"M Simmons","year":"2016","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pntd.0007860.ref050","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/AAC.49.3.952-958.2005","article-title":"Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis","volume":"49","author":"RA Larsen","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pntd.0007860.ref051","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1086\/507547","article-title":"Mycograb for the treatment of invasive candidiasis","volume":"43","author":"R Herbrecht","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pntd.0007860.ref052","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1080\/21645515.2017.1319021","article-title":"Antibody-mediated immunotherapy against chronic hepatitis B virus infection","volume":"13","author":"Y Gao","year":"2017","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"7","key":"pntd.0007860.ref053","doi-asserted-by":"crossref","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","article-title":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","author":"RTS'S Clinical Trials Partnership","year":"2014","journal-title":"PLoS Med"},{"issue":"26","key":"pntd.0007860.ref054","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1056\/NEJMe1606007","article-title":"Implementation of RTS,S\/AS01 Malaria Vaccine\u2014The Need for Further Evidence","volume":"374","author":"J Clemens","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"pntd.0007860.ref055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"NK Kisalu","year":"2018","journal-title":"Nat Med"},{"key":"pntd.0007860.ref056","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","author":"NK Kisalu","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"pntd.0007860.ref057","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.4049\/jimmunol.139.6.2044","article-title":"Production and properties of a mouse monoclonal IgE antibody to Schistosoma japonicum","volume":"139","author":"S Kojima","year":"1987","journal-title":"J Immunol"},{"issue":"Suppl 4","key":"pntd.0007860.ref058","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1590\/S0074-02761987000800045","article-title":"Role of a mouse monoclonal IgE antibody in passive transfer of immunity to Schistosoma japonicum infection","volume":"82","author":"S Kojima","year":"1987","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"8","key":"pntd.0007860.ref059","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/BF00928681","article-title":"Effects of heterologous helminth infections on passive transfer of immunity using a mouse monoclonal IgE antibody against Schistosoma japonicum","volume":"77","author":"T Janecharut","year":"1991","journal-title":"Parasitol Res"},{"issue":"5","key":"pntd.0007860.ref060","doi-asserted-by":"crossref","first-page":"e0007373","DOI":"10.1371\/journal.pntd.0007373","article-title":"A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis","volume":"13","author":"P MacGregor","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0007860.ref061","first-page":"37","article-title":"Immunotherapy for tuberculosis: future prospects","volume":"5","author":"G Abate","year":"2016","journal-title":"ImmunoTargets and therapy"},{"issue":"5","key":"pntd.0007860.ref062","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.4049\/jimmunol.1003189","article-title":"A novel human IgA monoclonal antibody protects against tuberculosis","volume":"186","author":"S Balu","year":"2011","journal-title":"J Immunol"},{"key":"pntd.0007860.ref063","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fimmu.2014.00296","article-title":"Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects","volume":"5","author":"OP Singh","year":"2014","journal-title":"Frontiers in immunology"},{"key":"pntd.0007860.ref064","unstructured":"World Health Organization. Schistosomiasis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schistosomiasis. 2019; [cited 2020 Jan 11]."},{"issue":"4","key":"pntd.0007860.ref065","doi-asserted-by":"crossref","first-page":"e0007025","DOI":"10.1371\/journal.pntd.0007025","article-title":"Female genital schistosomiasis and HIV\/AIDS: Reversing the neglect of girls and women","volume":"13","author":"PJ Hotez","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0007860.ref066","doi-asserted-by":"crossref","first-page":"e0004659","DOI":"10.1371\/journal.pntd.0004659","article-title":"High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni","volume":"10","author":"NR Mansour","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pntd.0007860.ref067","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2214-109X(17)30187-0","article-title":"Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial","volume":"5","author":"JT Coulibaly","year":"2017","journal-title":"The Lancet Global health"},{"issue":"2","key":"pntd.0007860.ref068","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1128\/AAC.05371-11","article-title":"In vivo activity of aryl ozonides against Schistosoma species","volume":"56","author":"J Keiser","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"9","key":"pntd.0007860.ref069","doi-asserted-by":"crossref","first-page":"e0005942","DOI":"10.1371\/journal.pntd.0005942","article-title":"Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model","volume":"11","author":"N Abla","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0007860.ref070","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10928-018-9601-1","article-title":"Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale","volume":"45","author":"PL Bonate","year":"2018","journal-title":"Journal of pharmacokinetics and pharmacodynamics"},{"issue":"3","key":"pntd.0007860.ref071","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0035-9203(85)90391-8","article-title":"Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses","volume":"79","author":"AE Butterworth","year":"1985","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"8","key":"pntd.0007860.ref072","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.4049\/jimmunol.140.8.2727","article-title":"Human resistance to Schistosoma mansoni is associated with IgG reactivity to a 37-kDa larval surface antigen","volume":"140","author":"AJ Dessein","year":"1988","journal-title":"J Immunol"},{"issue":"6306","key":"pntd.0007860.ref073","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/349243a0","article-title":"Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium","volume":"349","author":"P Hagan","year":"1991","journal-title":"Nature"},{"issue":"1","key":"pntd.0007860.ref074","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0169-4758(92)90303-J","article-title":"Reinfection, exposure and immunity in human schistosomiasis","volume":"8","author":"P Hagan","year":"1992","journal-title":"Parasitol Today"},{"issue":"2","key":"pntd.0007860.ref075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0166-6851(91)90015-X","article-title":"Paramyosin is the Schistosoma mansoni (Trematoda) homologue of antigen B from Taenia solium (Cestoda)","volume":"44","author":"JP Laclette","year":"1991","journal-title":"Mol Biochem Parasitol"},{"issue":"7","key":"pntd.0007860.ref076","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/intimm\/6.7.963","article-title":"Demonstration of the target molecule of a protective IgE antibody in secretory glands of Schistosoma japonicum larvae","volume":"6","author":"T Nara","year":"1994","journal-title":"Int Immunol"},{"issue":"1","key":"pntd.0007860.ref077","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0264-410X(96)00100-4","article-title":"The B cell epitope of paramyosin recognized by a protective monoclonal IgE antibody to Schistosoma japonicum","volume":"15","author":"T Nara","year":"1997","journal-title":"Vaccine"},{"issue":"15","key":"pntd.0007860.ref078","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1073\/pnas.85.15.5678","article-title":"Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen","volume":"85","author":"EJ Pearce","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"pntd.0007860.ref079","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1128\/IAI.00409-08","article-title":"Pilot-scale production and characterization of paramyosin, a vaccine candidate for schistosomiasis japonica","volume":"76","author":"M Jiz","year":"2008","journal-title":"Infect Immun"},{"issue":"9","key":"pntd.0007860.ref080","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1017\/S0031182012000273","article-title":"Parasite glycans and antibody-mediated immune responses in Schistosoma infection","volume":"139","author":"A van Diepen","year":"2012","journal-title":"Parasitology"},{"issue":"6","key":"pntd.0007860.ref081","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.copbio.2007.10.011","article-title":"Human monoclonal antibodies by immortalization of memory B cells","volume":"18","author":"A Lanzavecchia","year":"2007","journal-title":"Curr Opin Biotechnol"},{"issue":"4","key":"pntd.0007860.ref082","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nbt.2825","article-title":"Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery","volume":"32","author":"EC Lee","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"1","key":"pntd.0007860.ref083","first-page":"71","article-title":"Comparison of the protective efficacy on mekongi schistosomiasis in mice induced by antigens derived from cercariae, schistosomulae and adult worms","volume":"11","author":"W Usawattanakul","year":"1993","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"12","key":"pntd.0007860.ref084","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.4049\/jimmunol.156.12.4715","article-title":"Cytokine control of parasite-specific anergy in human urinary schistosomiasis. IL-10 modulates lymphocyte reactivity","volume":"156","author":"CL King","year":"1996","journal-title":"J Immunol"},{"issue":"9","key":"pntd.0007860.ref085","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nri1183","article-title":"Immune regulation by helminth parasites: cellular and molecular mechanisms","volume":"3","author":"RM Maizels","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"pntd.0007860.ref086","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.4049\/jimmunol.173.2.1240","article-title":"Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages","volume":"173","author":"P Smith","year":"2004","journal-title":"J Immunol"},{"issue":"4","key":"pntd.0007860.ref087","first-page":"57","article-title":"Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision","volume":"3","author":"F Bongomin","year":"2017","journal-title":"Journal of fungi (Basel, Switzerland)"},{"issue":"165","key":"pntd.0007860.ref088","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"GD Brown","year":"2012","journal-title":"Sci Transl Med"},{"issue":"3","key":"pntd.0007860.ref089","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tim.2014.01.001","article-title":"A neglected epidemic: fungal infections in HIV\/AIDS","volume":"22","author":"D Armstrong-James","year":"2014","journal-title":"Trends Microbiol"},{"issue":"1709","key":"pntd.0007860.ref090","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2015.0468","article-title":"Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized","volume":"371","author":"DW Denning","year":"2016","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"pntd.0007860.ref091","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"DM Saunte","year":"2017","journal-title":"The British journal of dermatology"},{"issue":"8","key":"pntd.0007860.ref092","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"R Rajasingham","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pntd.0007860.ref093","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1128\/IAI.55.3.749-752.1987","article-title":"Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody","volume":"55","author":"F Dromer","year":"1987","journal-title":"Infect Immun"},{"issue":"11","key":"pntd.0007860.ref094","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/IAI.60.11.4534-4541.1992","article-title":"Protective murine monoclonal antibodies to Cryptococcus neoformans","volume":"60","author":"J Mukherjee","year":"1992","journal-title":"Infect Immun"},{"issue":"8","key":"pntd.0007860.ref095","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1073\/pnas.90.8.3636","article-title":"Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection","volume":"90","author":"J Mukherjee","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pntd.0007860.ref096","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/IAI.62.3.1079-1088.1994","article-title":"Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice","volume":"62","author":"S Mukherjee","year":"1994","journal-title":"Infect Immun"},{"issue":"5","key":"pntd.0007860.ref097","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1128\/IAI.69.5.3410-3412.2001","article-title":"Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection","volume":"69","author":"AL Rosas","year":"2001","journal-title":"Infect Immun"},{"issue":"4","key":"pntd.0007860.ref098","doi-asserted-by":"crossref","first-page":"e5392","DOI":"10.1371\/journal.pone.0005392","article-title":"Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence","volume":"4","author":"A Torosantucci","year":"2009","journal-title":"PLoS ONE"},{"issue":"12","key":"pntd.0007860.ref099","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1128\/IAI.68.12.7049-7060.2000","article-title":"Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth","volume":"68","author":"ML Rodrigues","year":"2000","journal-title":"Infect Immun"},{"issue":"10","key":"pntd.0007860.ref100","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1128\/CVI.00202-07","article-title":"Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection","volume":"14","author":"ML Rodrigues","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"pntd.0007860.ref101","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fmicb.2011.00212","article-title":"Fungal glucosylceramides: from structural components to biologically active targets of new antimicrobials","volume":"2","author":"L Nimrichter","year":"2011","journal-title":"Frontiers in microbiology"},{"issue":"2","key":"pntd.0007860.ref102","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1469-0691.2011.03741.x","article-title":"Immunotherapy of Cryptococcus infections","volume":"18","author":"C Antachopoulos","year":"2012","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"issue":"4","key":"pntd.0007860.ref103","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1128\/IAI.74.4.2161-2168.2006","article-title":"Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis","volume":"74","author":"Q Zhou","year":"2006","journal-title":"Infect Immun"},{"issue":"2","key":"pntd.0007860.ref104","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1074\/jbc.M116.767582","article-title":"A Monoclonal Antibody to Cryptococcus neoformans Glucuronoxylomannan Manifests Hydrolytic Activity for Both Peptides and Polysaccharides","volume":"292","author":"A Bowen","year":"2017","journal-title":"J Biol Chem"},{"issue":"6","key":"pntd.0007860.ref105","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1128\/IAI.72.6.3674-3679.2004","article-title":"Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen","volume":"72","author":"LR Martinez","year":"2004","journal-title":"Infect Immun"},{"issue":"5","key":"pntd.0007860.ref106","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.chom.2012.04.004","article-title":"Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases","volume":"11","author":"A Casadevall","year":"2012","journal-title":"Cell host & microbe"},{"key":"pntd.0007860.ref107","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fphar.2019.00080","article-title":"The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses?","volume":"10","author":"T Di Mambro","year":"2019","journal-title":"Frontiers in pharmacology"},{"issue":"4","key":"pntd.0007860.ref108","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00850-16","article-title":"Immunization with Pneumocystis Cross-Reactive Antigen 1 (Pca1) Protects Mice against Pneumocystis Pneumonia and Generates Antibody to Pneumocystis jirovecii","volume":"85","author":"BL Tesini","year":"2017","journal-title":"Infect Immun"},{"issue":"10","key":"pntd.0007860.ref109","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/infdis\/jiw032","article-title":"Vaccine-Induced Immunogenicity and Protection Against Pneumocystis Pneumonia in a Nonhuman Primate Model of HIV and Pneumocystis Coinfection","volume":"213","author":"HM Kling","year":"2016","journal-title":"J Infect Dis"},{"issue":"3","key":"pntd.0007860.ref110","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/IAI.70.3.1069-1074.2002","article-title":"Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia","volume":"70","author":"F Gigliotti","year":"2002","journal-title":"Infect Immun"},{"issue":"3","key":"pntd.0007860.ref111","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1165\/rcmb.2016-0360ED","article-title":"An Emerging Role of B Cell Immunity in Susceptibility to Pneumocystis Pneumonia","volume":"56","author":"JK Kolls","year":"2017","journal-title":"American journal of respiratory cell and molecular biology"},{"issue":"7","key":"pntd.0007860.ref112","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1128\/IAI.00349-08","article-title":"The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB\/c mice challenged intratracheally with the fungus","volume":"76","author":"R Buissa-Filho","year":"2008","journal-title":"Infect Immun"},{"issue":"11","key":"pntd.0007860.ref113","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1128\/IAI.71.11.6534-6542.2003","article-title":"Characterization of gp70 and anti-gp70 monoclonal antibodies in Paracoccidioides brasiliensis pathogenesis","volume":"71","author":"D de Mattos Grosso","year":"2003","journal-title":"Infect Immun"},{"issue":"2","key":"pntd.0007860.ref114","first-page":"171","article-title":"Candida albicans, a major human fungal pathogen","volume":"49","author":"J Kim","year":"2011","journal-title":"Journal of microbiology (Seoul, Korea)"},{"issue":"1","key":"pntd.0007860.ref115","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1038\/s41467-018-07738-1","article-title":"Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis","volume":"9","author":"FM Rudkin","year":"2018","journal-title":"Nature communications"},{"issue":"12","key":"pntd.0007860.ref116","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2217\/imt.12.127","article-title":"Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections","volume":"4","author":"R Pikman","year":"2012","journal-title":"Immunotherapy"},{"issue":"8","key":"pntd.0007860.ref117","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/08820139.2015.1093913","article-title":"Immunotherapy of Fungal Infections","volume":"44","author":"K Datta","year":"2015","journal-title":"Immunological investigations"},{"issue":"7446","key":"pntd.0007860.ref118","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"S Bhatt","year":"2013","journal-title":"Nature"},{"issue":"Suppl 4","key":"pntd.0007860.ref119","doi-asserted-by":"crossref","first-page":"S830","DOI":"10.1093\/clinids\/11.Supplement_4.S830","article-title":"Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade","volume":"11","author":"SB Halstead","year":"1989","journal-title":"Rev Infect Dis"},{"issue":"6","key":"pntd.0007860.ref120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/rmv.405","article-title":"Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications","volume":"13","author":"A Takada","year":"2003","journal-title":"Reviews in medical virology"},{"issue":"50","key":"pntd.0007860.ref121","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2015.09.108","article-title":"Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward","volume":"33","author":"B Guy","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"pntd.0007860.ref122","doi-asserted-by":"crossref","first-page":"e0005179","DOI":"10.1371\/journal.pntd.0005179","article-title":"The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries","volume":"10","author":"M Aguiar","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"5596","key":"pntd.0007860.ref123","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/265739a0","article-title":"Antibody-enhanced dengue virus infection in primate leukocytes","volume":"265","author":"SB Halstead","year":"1977","journal-title":"Nature"},{"issue":"23","key":"pntd.0007860.ref124","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.vaccine.2013.03.038","article-title":"Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation","volume":"31","author":"Live Dengue Vaccines Technical Consultation Reporting G","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"pntd.0007860.ref125","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/infdis\/jis744","article-title":"Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines","volume":"207","author":"W Sun","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"pntd.0007860.ref126","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.imbio.2011.07.008","article-title":"Mycobacterium tuberculosis: immune evasion, latency and reactivation","volume":"217","author":"A Gupta","year":"2012","journal-title":"Immunobiology"},{"key":"pntd.0007860.ref127","doi-asserted-by":"crossref","DOI":"10.5772\/53950","article-title":"The Role of Antibodies in the Defense Against Tuberculosis","author":"A Acosta","year":"2013","journal-title":"Tuberculosis\u2014Current Issues in Diagnosis and Management"},{"key":"pntd.0007860.ref128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fmicb.2014.00249","article-title":"Malaria drives T cells to exhaustion","volume":"5","author":"MN Wykes","year":"2014","journal-title":"Frontiers in microbiology"},{"issue":"5111","key":"pntd.0007860.ref129","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/216160a0","article-title":"Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei","volume":"216","author":"RS Nussenzweig","year":"1967","journal-title":"Nature"},{"key":"pntd.0007860.ref130","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd4683","article-title":"Hit and lead criteria in drug discovery for infectious diseases of the developing world","volume":"14","author":"K Katsuno","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"pntd.0007860.ref131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"JN Burrows","year":"2017","journal-title":"Malar J"},{"issue":"1","key":"pntd.0007860.ref132","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92587","article-title":"Assessing drug efficacy against Plasmodium falciparum liver stages in vivo","volume":"3","author":"EL Flannery","year":"2018","journal-title":"JCI insight"},{"issue":"48","key":"pntd.0007860.ref133","doi-asserted-by":"crossref","first-page":"E10438","DOI":"10.1073\/pnas.1715812114","article-title":"Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein","volume":"114","author":"D Oyen","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pntd.0007860.ref134","article-title":"A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein","author":"J Tan","year":"2018","journal-title":"Nat Med"},{"issue":"21","key":"pntd.0007860.ref135","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96381","article-title":"Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions","volume":"2","author":"RO Payne","year":"2017","journal-title":"JCI insight"},{"key":"pntd.0007860.ref136","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.3389\/fimmu.2018.02866","article-title":"KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization","volume":"9","author":"G Kamuyu","year":"2018","journal-title":"Frontiers in immunology"},{"issue":"1","key":"pntd.0007860.ref137","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cell.2019.05.025","article-title":"Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies","volume":"178","author":"DGW Alanine","year":"2019","journal-title":"Cell"},{"issue":"2","key":"pntd.0007860.ref138","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.immuni.2016.07.017","article-title":"Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity","volume":"45","author":"DS Karunarathne","year":"2016","journal-title":"Immunity"},{"key":"pntd.0007860.ref139","first-page":"8724549","article-title":"Antibody-Mediated Therapy against HIV\/AIDS: Where Are We Standing Now?","volume":"2018","author":"NJ Awi","year":"2018","journal-title":"Journal of pathogens"},{"issue":"4","key":"pntd.0007860.ref140","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"M Caskey","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"pntd.0007860.ref141","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/COH.0000000000000479","article-title":"The return of PRO 140, a CCR5-directed mAb","volume":"13","author":"MA Thompson","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"pntd.0007860.ref142","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3389\/fimmu.2018.01839","article-title":"APOBEC3G\/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz","volume":"9","author":"DA Covino","year":"2018","journal-title":"Frontiers in immunology"},{"issue":"4","key":"pntd.0007860.ref143","doi-asserted-by":"crossref","first-page":"e0125704","DOI":"10.1371\/journal.pone.0125704","article-title":"A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity","volume":"10","author":"A Cerino","year":"2015","journal-title":"PLoS ONE"},{"issue":"2","key":"pntd.0007860.ref144","doi-asserted-by":"crossref","first-page":"e0004415","DOI":"10.1371\/journal.pntd.0004415","article-title":"Combined Immune Therapy for the Treatment of Visceral Leishmaniasis","volume":"10","author":"RJ Faleiro","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0007860.ref145","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"L Dyck","year":"2017","journal-title":"Eur J Immunol"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0007860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T22:38:48Z","timestamp":1695681528000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0007860"}},"subtitle":[],"editor":[{"given":"Katharina","family":"Roeltgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":145,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0007860","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}